{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:24:30Z","timestamp":1788463470764,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00066-022-02026-w","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T19:10:54Z","timestamp":1669835454000},"page":"456-464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a\u00a0multi-institutional study"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-9021","authenticated-orcid":false,"given":"Cem","family":"Onal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi","family":"Oymak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan Cem","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guler","family":"Yavas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pervin","family":"Hurmuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagdas","family":"Yavas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokhan","family":"Ozyigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"issue":"2","key":"2026_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.6004\/jnccn.2014.0018","volume":"12","author":"RJ Motzer","year":"2014","unstructured":"Motzer\u00a0RJ, Jonasch\u00a0E, Agarwal\u00a0N et\u00a0al (2014) Kidney cancer, version 2.2014. J\u00a0Natl Compr Canc Netw 12(2):175\u2013182. https:\/\/doi.org\/10.6004\/jnccn.2014.0018","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2026_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel\u00a0RL, Miller\u00a0KD, Jemal\u00a0A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2026_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ctrv.2011.06.011","volume":"38","author":"SL Wood","year":"2012","unstructured":"Wood\u00a0SL, Brown\u00a0JE (2012) Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 38(4):284\u2013291. https:\/\/doi.org\/10.1016\/j.ctrv.2011.06.011","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"2026_CR4","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","volume":"20","author":"RJ Motzer","year":"2019","unstructured":"Motzer\u00a0RJ, Rini\u00a0BI, McDermott\u00a0DF et al (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a\u00a0randomised, controlled, phase 3 trial. Lancet Oncol 20(10):1370\u20131385. https:\/\/doi.org\/10.1016\/S1470-2045(19)30413-9","journal-title":"Lancet Oncol"},{"issue":"14","key":"2026_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer\u00a0RJ, Tannir\u00a0NM, McDermott\u00a0DF et al (2018) Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N\u00a0Engl J Med 378(14):1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"issue":"12","key":"2026_CR6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini\u00a0BI, Plimack\u00a0ER, Stus\u00a0V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N\u00a0Engl J Med 380(12):1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"issue":"12","key":"2026_CR7","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","volume":"15","author":"S Dabestani","year":"2014","unstructured":"Dabestani\u00a0S, Marconi\u00a0L, Hofmann\u00a0F et\u00a0al (2014) Local treatments for metastases of renal cell carcinoma: a\u00a0systematic review. Lancet Oncol 15(12):e549\u2013561. https:\/\/doi.org\/10.1016\/S1470-2045(14)70235-9","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.eururo.2017.03.005","volume":"72","author":"CP Meyer","year":"2017","unstructured":"Meyer\u00a0CP, Sun\u00a0M, Karam\u00a0JA et al (2017) Complications after metastasectomy for renal cell carcinoma\u2014a population-based assessment. Eur Urol 72(2):171\u2013174. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.005","journal-title":"Eur Urol"},{"issue":"14","key":"2026_CR9","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1158\/1078-0432.CCR-12-0002","volume":"18","author":"AW Griffioen","year":"2012","unstructured":"Griffioen\u00a0AW, Mans\u00a0LA, de Graaf\u00a0AMA et\u00a0al (2012) Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 18(14):3961\u20133971. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0002","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.juro.2018.08.049","volume":"201","author":"C Franzese","year":"2019","unstructured":"Franzese\u00a0C, Franceschini\u00a0D, Di Brina\u00a0L et\u00a0al (2019) Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma. J\u00a0Urol 201(1):70\u201375. https:\/\/doi.org\/10.1016\/j.juro.2018.08.049","journal-title":"J Urol"},{"issue":"3","key":"2026_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.radonc.2018.04.028","volume":"127","author":"M Stenman","year":"2018","unstructured":"Stenman\u00a0M, Sinclair\u00a0G, Paavola\u00a0P et\u00a0al (2018) Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005\u20132014. Radiother Oncol 127(3):501\u2013506. https:\/\/doi.org\/10.1016\/j.radonc.2018.04.028","journal-title":"Radiother Oncol"},{"issue":"8","key":"2026_CR12","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s12094-022-02793-z","volume":"24","author":"C Onal","year":"2022","unstructured":"Onal\u00a0C, Hurmuz\u00a0P, Guler\u00a0OC et\u00a0al (2022) The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma. Clin Transl Oncol 24(8):1533\u20131541. https:\/\/doi.org\/10.1007\/s12094-022-02793-z","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"2026_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.eururo.2006.03.021","volume":"50","author":"L Walsh","year":"2006","unstructured":"Walsh\u00a0L, Stanfield\u00a0JL, Cho\u00a0LC et al (2006) Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a\u00a0nude mouse model. Eur Urol 50(4):795\u2013800. https:\/\/doi.org\/10.1016\/j.eururo.2006.03.021 (discussion 800)","journal-title":"Eur Urol"},{"issue":"4","key":"2026_CR14","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1016\/S1470-2045(13)70569-2","volume":"15","author":"G De Meerleer","year":"2014","unstructured":"De Meerleer\u00a0G, Khoo\u00a0V, Escudier\u00a0B et al (2014) Radiotherapy for renal-cell carcinoma. Lancet Oncol 15(4):e170\u2013177. https:\/\/doi.org\/10.1016\/S1470-2045(13)70569-2","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11523-013-0280-y","volume":"9","author":"J Kao","year":"2014","unstructured":"Kao\u00a0J, Chen\u00a0CT, Tong\u00a0CC et\u00a0al (2014) Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a\u00a0prospective clinical trial. Target Oncol 9(2):145\u2013153. https:\/\/doi.org\/10.1007\/s11523-013-0280-y","journal-title":"Target Oncol"},{"issue":"6","key":"2026_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","volume":"80","author":"P Cheung","year":"2021","unstructured":"Cheung\u00a0P, Patel\u00a0S, North\u00a0SA et\u00a0al (2021) Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur Urol 80(6):693\u2013700. https:\/\/doi.org\/10.1016\/j.eururo.2021.07.026","journal-title":"Eur Urol"},{"issue":"3","key":"2026_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.urolonc.2010.02.006","volume":"30","author":"M Staehler","year":"2012","unstructured":"Staehler\u00a0M, Haseke\u00a0N, Stadler\u00a0T et al (2012) Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer. Urol Oncol 30(3):290\u2013293. https:\/\/doi.org\/10.1016\/j.urolonc.2010.02.006","journal-title":"Urol Oncol"},{"issue":"1","key":"2026_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/coc.0000000000000622","volume":"43","author":"L He","year":"2020","unstructured":"He\u00a0L, Liu\u00a0Y, Han\u00a0H et\u00a0al (2020) Survival outcomes after adding stereotactic body radiotherapy to metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Am J Clin Oncol 43(1):58\u201363. https:\/\/doi.org\/10.1097\/coc.0000000000000622","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"2026_CR19","doi-asserted-by":"publisher","first-page":"7037","DOI":"10.21873\/anticanres.14730","volume":"40","author":"V Gebbia","year":"2020","unstructured":"Gebbia\u00a0V, Girlando\u00a0A et al (2020) Stereotactic radiotherapy for the treatment of patients with oligo-progressive metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitor: data from the real world. Anticancer Res 40(12):7037\u20137043. https:\/\/doi.org\/10.21873\/anticanres.14730","journal-title":"Anticancer Res"},{"key":"2026_CR20","doi-asserted-by":"publisher","first-page":"607595","DOI":"10.3389\/fonc.2021.607595","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu\u00a0Y, Zhang\u00a0Z, Han\u00a0H et\u00a0al (2021) Survival after combining stereotactic body radiation therapy and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Front Oncol 11:607595. https:\/\/doi.org\/10.3389\/fonc.2021.607595","journal-title":"Front Oncol"},{"key":"2026_CR21","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3389\/fonc.2020.01246","volume":"10","author":"M Khan","year":"2020","unstructured":"Khan\u00a0M, Zhao\u00a0Z, Arooj\u00a0S et\u00a0al (2020) Impact of tyrosine kinase inhibitors (TKis) combined with radiation therapy for the management of brain metastases from renal cell carcinoma. Front Oncol 10:1246. https:\/\/doi.org\/10.3389\/fonc.2020.01246","journal-title":"Front Oncol"},{"issue":"12","key":"2026_CR22","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E","volume":"80","author":"S Ning","year":"1997","unstructured":"Ning\u00a0S, Trisler\u00a0K, Wessels\u00a0BW et al (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80(12):2519\u20132528. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19971215)80:12+\u30082519::aid-cncr26\u30093.3.co;2\u2011t","journal-title":"Cancer"},{"issue":"4","key":"2026_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","volume":"18","author":"RD Timmerman","year":"2008","unstructured":"Timmerman\u00a0RD (2008) An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol 18(4):215\u2013222. https:\/\/doi.org\/10.1016\/j.semradonc.2008.04.001","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"2026_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer\u00a0EA, Therasse\u00a0P, Bogaerts\u00a0J et\u00a0al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2026_CR25","doi-asserted-by":"publisher","first-page":"176373","DOI":"10.1155\/2015\/176373","volume":"2015","author":"X Yu","year":"2015","unstructured":"Yu\u00a0X, Wang\u00a0B, Li\u00a0X et\u00a0al (2015) The significance of metastasectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy. Biomed Res Int 2015:176373. https:\/\/doi.org\/10.1155\/2015\/176373","journal-title":"Biomed Res Int"},{"issue":"5","key":"2026_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","volume":"2","author":"NG Zaorsky","year":"2019","unstructured":"Zaorsky\u00a0NG, Lehrer\u00a0EJ, Kothari\u00a0G et al (2019) Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a\u00a0meta-analysis of 28\u00a0studies. Eur Urol 2(5):515\u2013523. https:\/\/doi.org\/10.1016\/j.euo.2019.05.007","journal-title":"Eur Urol"},{"issue":"1","key":"2026_CR27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","volume":"7","author":"BI Rini","year":"2019","unstructured":"Rini\u00a0BI, Battle\u00a0D, Figlin\u00a0RA et\u00a0al (2019) The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J\u00a0Immunother Cancer 7(1):354. https:\/\/doi.org\/10.1186\/s40425-019-0813-8","journal-title":"J Immunother Cancer"},{"key":"2026_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-022-01962-x","author":"C Onal","year":"2022","unstructured":"Onal\u00a0C, Guler\u00a0OC, Hurmuz\u00a0P et al (2022) Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a\u00a0multi-institutional study. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-022-01962-x","journal-title":"Strahlenther Onkol"},{"key":"2026_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","volume":"53","author":"SG Kroeze","year":"2017","unstructured":"Kroeze\u00a0SG, Fritz\u00a0C, Hoyer\u00a0M et\u00a0al (2017) Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev 53:25\u201337. https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.013","journal-title":"Cancer Treat Rev"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-02026-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-022-02026-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-02026-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T09:03:47Z","timestamp":1682499827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-022-02026-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1007\/s00066-022-02026-w","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"19 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.\u00a0Onal, E.\u00a0Oymak, O.C.\u00a0Guler, B.\u00a0Tilki, G.\u00a0Yavas, P.\u00a0Hurmuz, C.\u00a0Yavas, and G.\u00a0Ozyigit declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Baskent University Institutional Review Board (project no: KA22\/313) and supported by the Baskent University Research Fund.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}